Literature DB >> 3549473

Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease.

C Manniche, A Malchow-Møller, J R Andersen, C Pedersen, T M Hansen, P Jess, L Helleberg, S N Rasmussen, U Tage-Jensen, S E Nielsen.   

Abstract

Sixty-seven patients with rheumatic disease, treated with non-steroidal anti-inflammatory drugs (NSAIDs), entered a controlled trial with a diagnosis of duodenal (n = 51), gastric (n = 14), or gastric and duodenal (n = 2) ulcers. The main objectives of the study were a comparison of ranitidine and sucralfate in ulcer treatment, and to observe the influence of continued NSAID administration during peptic ulcer therapy. Ulcers healed within nine weeks in 52 patients. The mean healing time was similar in 27 patients given ranitidine 150 mg bd (4.9 weeks) and 25 patients given sucralfate 1 g qid (4.6 weeks). In patients with unhealed ulcers after nine weeks of treatment, healing was obtained in seven after further therapy for 3-9 weeks. Of the 30 patients who continued NSAIDs during treatment with either ranitidine or sucralfate, 23 ulcers healed (mean healing time: 5.0 weeks). Of 32 patients in whom NSAIDs were stopped, ulcer healing was documented in 29 (mean healing time: 4.6 weeks). The difference in healing rates was not statistically significant (p greater than 0.10). The outcome of ulcer treatment did not differ in patients with rheumatoid arthritis and patients suffering from osteoarthritis. During a 12 month follow up 14 symptomatic ulcer recurrences were recorded.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549473      PMCID: PMC1432982          DOI: 10.1136/gut.28.2.226

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  Upper gastrointestinal disease in rheumatoid arthritis.

Authors:  D C Sun; S H Roth; C S Mitchell; D W Englund
Journal:  Am J Dig Dis       Date:  1974-05

Review 2.  Ranitidine: a new H2-receptor antagonist.

Authors:  J B Zeldis; L S Friedman; K J Isselbacher
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

3.  Placebos in clinical trials of duodenal ulcer: the end of an era?

Authors:  W L Peterson; J Elashoff
Journal:  Gastroenterology       Date:  1980-09       Impact factor: 22.682

4.  Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.

Authors:  K Somerville; G Faulkner; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

5.  Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy.

Authors:  G R Silvoso; K J Ivey; J H Butt; O O Lockard; S D Holt; C Sisk; W N Baskin; P A Mackercher; J Hewett
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

Review 6.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

7.  Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up.

Authors:  J C O'Laughlin; G K Silvoso; K J Ivey
Journal:  Dig Dis Sci       Date:  1982-11       Impact factor: 3.199

8.  Gastroscopic evaluation of anti-inflammatory agents.

Authors:  I Caruso; G Bianchi Porro
Journal:  Br Med J       Date:  1980-01-12

9.  Reappraisal of the effects of aspirin on the stomach.

Authors:  W D Rees; L A Turnberg
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

10.  Cimetidine for peptic ulcer in patients with arthritis.

Authors:  J R Croker; P B Cotton; A C Boyle; P Kinsella
Journal:  Ann Rheum Dis       Date:  1980-06       Impact factor: 19.103

View more
  25 in total

Review 1.  Mechanisms of NSAID-induced gastroenteropathy.

Authors:  A H Price; M Fletcher
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Non-steroidal anti-inflammatory drug-induced gastropathy. Mechanisms and management.

Authors:  S Szabo; W F Spill; K D Rainsford
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 3.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit.

Authors:  C W Howden
Journal:  BMJ       Date:  1988-11-26

Review 5.  The role of prostaglandins in gastric mucosal protection.

Authors:  D E Wilson
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

Review 6.  Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

Authors:  J G Penston; K G Wormsley
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study.

Authors:  A L Blum; H Bethge; J C Bode; W Domschke; G Feurle; K Hackenberg; B Hammer; W Hüttemann; M Jung; G Kachel
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

Review 8.  Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: to be considered in certain circumstances.

Authors:  M Doherty
Journal:  BMJ       Date:  1989-01-21

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; M Balsitis; S Everitt; C J Hawkey
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.